We recently announced a collaboration with Helix, a personal genomics company, to build clinician-approved genetic testing applications for proactive health. These health "apps" combine Helix's DNA sequencing platform and Invitae's clinical expertise.
Healthy individuals who utilize the Helix consumer platform will be able to select health applications from Invitae pending approval by a clinician. Invitae will then provide a full interpretation of the results, with a focus on actionable findings related to cancer and cardiovascular disease.
The Helix apps will complement Invitae’s existing menu of high-quality genetic testing, which will continue to be based in Invitae’s own College of American Pathologists (CAP)-accredited and Clinical Laboratory Improvement Amendments (CLIA)-certified clinical diagnostic laboratory.
Invitae’s health-related scans on the Helix platform are expected to be available in 2017.